MicroRNAs as possible biomarkers for diagnosis and prognosis of hepatitis b-and c-related-hepatocellularcarcinoma

World Journal of Gastroenterology

Volumn 22, Issue 15, 2016, Pages 3907-3936

  Fiorino, Sirio ^a   Bacchi Reggiani, Maria Letizia ^b   Visani, Michela ^c   Acquaviva, Giorgia ^c   Fornelli, Adele ^a   Masetti, Michele ^a   Tura, Andrea ^d,e   Grizzi, Fabio ^f   Zanello, Matteo ^a   Mastrangelo, Laura ^a   Lombardi, Raffaele ^a   Di Tommaso, Luca ^f   Bondi, Arrigo ^a   Sabbatani, Sergio ^b   Domanico, Andrea ^a   Fabbri, Carlo ^a   Leandri, Paolo ^a   Pession, Annalisa ^c   Jovine, Elio ^a   De Biase, Dario ^c  

^a MAGGIORE HOSPITAL   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d CNR   (Italy)

^e CNR Institute of Neuroscience ^*  (Italy)

^f HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinomas; Liver diseases; MicroRNAs; Review

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 122; MICRORNA 125A; MICRORNA 125B; MICRORNA 199A; MICRORNA 199B; MICRORNA 21; MICRORNA 221; MICRORNA 222; MICRORNA 223; MICRORNA 224; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; GENE EXPRESSION; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOLECULAR DIAGNOSIS; NONHUMAN; SYSTEMATIC REVIEW (TOPIC); VIRUS CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; COMPLICATION; EARLY CANCER DIAGNOSIS; GENETICS; LIVER NEOPLASMS; PREDICTIVE VALUE; PROGNOSIS;

BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; EARLY DETECTION OF CANCER; HEPATITIS B; HEPATITIS C; HUMANS; LIVER NEOPLASMS; MICRORNAS; MOLECULAR DIAGNOSTIC TECHNIQUES; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 84963540228     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i15.3907     Document Type: Article

References (110)

1. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264-1273.e1 [PMID: 22537432 DOI: 10.1053/j.gastro.2011.12.061]
2. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29 Suppl 1: 74-81 [PMID: 19207969 DOI: 10.1111/j.1478-3231.2008.01934.x]
3. Lee MH, Yang HI, Yuan Y, L'Italien G, Chen CJ. Epidemiology and natural history of hepatitis C virus infection. World J Gastroenterol 2014; 20: 9270-9280 [PMID: 25071320 DOI: 10.3748/wjg.v20.i28.9270]
4. Liu CJ, Kao JH. Global perspective on the natural history of chronic hepatitis B: role of hepatitis B virus genotypes A to J. Semin Liver Dis 2013; 33: 97-102 [PMID: 23749665 DOI: 10.1055/s-0033-1345716]
5. Fiorino S, Bacchi-Reggiani L, Pontoriero L, Gallo C, Chili E, Masetti M, Zanini N, Grondona A, Silvestri T, Deleonardi G, Fornelli A, Bondi A, de Biase D, Baccarini P, Tallini G, Tropeano A, Quartuccio V, Cuppini A, Castellani G, Jovine E. Tensegrity model hypothesis: may this paradigm be useful to explain hepatic and pancreatic carcinogenesis in patients with persistent hepatitis B or hepatitis C virus infection? JOP 2014; 15: 151-164 [PMID: 24618442 DOI: 10.6092/1590-8577/2099]
6. Ji X, Zhang Q, Du Y, Liu W, Li Z, Hou X, Cao G. Somatic mutations, viral integration and epigenetic modification in the evolution of hepatitis B virus-induced hepatocellular carcinoma. Curr Genomics 2014; 15: 469-480 [PMID: 25646075 DOI: 10.217 4/1389202915666141114213833]
7. Xu C, Zhou W, Wang Y, Qiao L. Hepatitis B virus-induced hepatocellular carcinoma. Cancer Lett 2014; 345: 216-222 [PMID: 23981576 DOI: 10.1016/j.canlet.2013.08.035]
8. Dandri M, Locarnini S. New insight in the pathobiology of hepatitis B virus infection. Gut 2012; 61 Suppl 1: i6-i17 [PMID: 22504921 DOI: 10.1136/gutjnl-2012-302056]
9. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 Lyon, France: International Agency for Research on Cancer, 2013
10. Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 2010; 42 Suppl 3: S206-S214 [PMID: 20547305 DOI: 10.1016/S1590-8658(10)60507-5]
11. Attwa MH, El-Etreby SA. Guide for diagnosis and treatment of hepatocellular carcinoma. World J Hepatol 2015; 7: 1632-1651 [PMID: 26140083 DOI: 10.4254/wjh.v7.i12.1632]
12. Bodzin AS, Busuttil RW. Hepatocellular carcinoma: Advances in diagnosis, management, and long term outcome. World J Hepatol 2015; 7: 1157-1167 [PMID: 26019732 DOI: 10.4254/wjh. v7.i9.1157]
13. Filipowicz W, Jaskiewicz L, Kolb FA, Pillai RS. Post-transcriptional gene silencing by siRNAs and miRNAs. Curr Opin Struct Biol 2005; 15: 331-341 [PMID: 15925505 DOI: 10.1016/j.sbi.2005.05.006]
14. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004; 5: 522-531 [PMID: 15211354 DOI: 10.1038/nrg1379]
15. Takasaki S. Roles of microRNAs in cancers and development. Methods Mol Biol 2015; 1218: 375-413 [PMID: 25319665 DOI: 10.1007/978-1-4939-1538-524]
16. Galasso M, Sandhu SK, Volinia S. MicroRNA expression signatures in solid malignancies. Cancer J 2012; 18: 238-243 [PMID: 22647360 DOI: 10.1097/PPO.0b013e318258b5f4]
17. Lynam-Lennon N, Maher SG, Reynolds JV. The roles of microRNA in cancer and apoptosis. Biol Rev Camb Philos Soc 2009; 84: 55-71 [PMID: 19046400 DOI: 10.1111/j.1469-185X.2008.00061.x]
18. Nana-Sinkam SP, Croce CM. Clinical applications for microRNAs in cancer. Clin Pharmacol Ther 2013; 93: 98-104 [PMID: 23212103 DOI: 10.1038/clpt.2012.192]
19. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007; 302: 1-12 [PMID: 16989803 DOI: 10.1016/j.ydbio.2006.08.028]
20. Piva R, Spandidos DA, Gambari R. From microRNA functions to microRNA therapeutics: novel targets and novel drugs in breast cancer research and treatment (Review). Int J Oncol 2013; 43: 985-994 [PMID: 23939688 DOI: 10.3892/ijo.2013.2059]
21. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151: 264-269, W64 [PMID: 19622511]
22. Bandopadhyay M, Banerjee A, Sarkar N, Panigrahi R, Datta S, Pal A, Singh SP, Biswas A, Chakrabarti S, Chakravarty R. Tumor suppressor micro RNA miR-145 and onco micro RNAs miR-21 and miR-222 expressions are differentially modulated by hepatitis B virus X protein in malignant hepatocytes. BMC Cancer 2014; 14: 721 [PMID: 25260533 DOI: 10.1186/1471-2407-14-721]
23. Cheong JY, Shin HD, Cho SW, Kim YJ. Association of polymorphism in microRNA 604 with susceptibility to persistent hepatitis B virus infection and development of hepatocellular carcinoma. J Korean Med Sci 2014; 29: 1523-1527 [PMID: 25408584 DOI: 10.3346/jkms.2014.29.11.1523]
24. Connolly E, Melegari M, Landgraf P, Tchaikovskaya T, Tennant BC, Slagle BL, Rogler LE, Zavolan M, Tuschl T, Rogler CE. Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype. Am J Pathol 2008; 173: 856-864 [PMID: 18688024 DOI: 10.2353/ajpath.2008.080096]
25. Coppola N, Potenza N, Pisaturo M, Mosca N, Tonziello G, Signoriello G, Messina V, Sagnelli C, Russo A, Sagnelli E. Liver microRNA hsa-miR-125a-5p in HBV chronic infection: correlation with HBV replication and disease progression. PLoS One 2013; 8: e65336 [PMID: 23843939 DOI: 10.1371/journal.pone.0065336]
26. Dang YW, Zeng J, He RQ, Rong MH, Luo DZ, Chen G. Effects of miR-152 on cell growth inhibition, motility suppression and apoptosis induction in hepatocellular carcinoma cells. Asian Pac J Cancer Prev 2014; 15: 4969-4976 [PMID: 24998573]
27. Fan MQ, Huang CB, Gu Y, Xiao Y, Sheng JX, Zhong L. Decrease expression of microRNA-20a promotes cancer cell proliferation and predicts poor survival of hepatocellular carcinoma. J Exp Clin Cancer Res 2013; 32: 21 [PMID: 23594563 DOI: 10.1186/1756-9966-32-21]
28. Fu Y, Wei X, Tang C, Li J, Liu R, Shen A, Wu Z. Circulating microRNA-101 as a potential biomarker for hepatitis B virus-related hepatocellular carcinoma. Oncol Lett 2013; 6: 1811-1815 [PMID: 24260081 DOI: 10.3892/ol.2013.1638]
29. Gao P, Wong CC, Tung EK, Lee JM, Wong CM, Ng IO. Deregulation of microRNA expression occurs early and accumulates in early stages of HBV-associated multistep hepatocarcinogenesis. J Hepatol 2011; 54: 1177-1184 [PMID: 21145831 DOI: 10.1016/j.jhep.2010.09.023]
30. Giray BG, Emekdas G, Tezcan S, Ulger M, Serin MS, Sezgin O, Altintas E, Tiftik EN. Profiles of serum microRNAs; miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma. Mol Biol Rep 2014; 41: 4513-4519 [PMID: 24595450 DOI: 10.1007/s11033-014-3322-3]
31. Gu H, Guo X, Zou L, Zhu H, Zhang J. Upregulation of microRNA-372 associates with tumor progression and prognosis in hepatocellular carcinoma. Mol Cell Biochem 2013; 375: 23-30 [PMID: 23291979 DOI: 10.1007/s11010-012-1521-6]
32. Gui J, Tian Y, Wen X, Zhang W, Zhang P, Gao J, Run W, Tian L, Jia X, Gao Y. Serum microRNA characterization identifes miR-885-5p as a potential marker for detecting liver pathologies. Clin Sci (Lond) 2011; 120: 183-193 [PMID: 20815808 DOI: 10.1042/CS20100297]
33. Han Y, Pu R, Han X, Zhao J, Zhang Y, Zhang Q, Yin J, Xie J, Shen Q, Deng Y, Ding Y, Li W, Li J, Zhang H, Cao G. Associations of pri-miR-34b/c and pre-miR-196a2 polymorphisms and their multiplicative interactions with hepatitis B virus mutations with hepatocellular carcinoma risk. PLoS One 2013; 8: e58564 [PMID: 23516510 DOI: 10.1371/journal.pone.0058564]
34. Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong Q, Qin L, Wu X, Zheng Y, Yang Y, Tian W, Zhang Q, Wang C, Zhang Q, Zhuang SM, Zheng L, Liang A, Tao W, Cao X. Identifcation of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 2011; 19: 232-243 [PMID: 21316602 DOI: 10.1016/j.ccr.2011.01.001]
35. Huang J, Wang Y, Guo Y, Sun S. Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology 2010; 52: 60-70 [PMID: 20578129 DOI: 10.1002/hep.23660]
36. Huang YH, Lin KH, Chen HC, Chang ML, Hsu CW, Lai MW, Chen TC, Lee WC, Tseng YH, Yeh CT. Identification of postoperative prognostic microRNA predictors in hepatocellular carcinoma. PLoS One 2012; 7: e37188 [PMID: 22629365 DOI: 10.1371/journal.pone.0037188]
37. Jiang R, Deng L, Zhao L, Li X, Zhang F, Xia Y, Gao Y, Wang X, Sun B. miR-22 promotes HBV-related hepatocellular carcinoma development in males. Clin Cancer Res 2011; 17: 5593-5603 [PMID: 21750200 DOI: 10.1158/1078-0432.CCR-10-1734]
38. Kim HY, Yoon JH, Lee HS, Cheong JY, Cho SW, Shin HD, Kim YJ. MicroRNA-196A-2 polymorphisms and hepatocellular carcinoma in patients with chronic hepatitis B. J Med Virol 2014; 86: 446-453 [PMID: 24248733 DOI: 10.1002/jmv.23848]
39. Kwak MS, Lee DH, Cho Y, Cho EJ, Lee JH, Yu SJ, Yoon JH, Lee HS, Kim CY, Cheong JY, Cho SW, Shin HD, Kim YJ. Association of polymorphism in pri-microRNAs-371-372-373 with the occurrence of hepatocellular carcinoma in hepatitis B virus infected patients. PLoS One 2012; 7: e41983 [PMID: 22848681 DOI: 10.1371/journal.pone.0041983]
40. Lan SH, Wu SY, Zuchini R, Lin XZ, Su IJ, Tsai TF, Lin YJ, Wu CT, Liu HS. Autophagy suppresses tumorigenesis of hepatitis B virus-associated hepatocellular carcinoma through degradation of microRNA-224. Hepatology 2014; 59: 505-517 [PMID: 23913306 DOI: 10.1002/hep.26659]
41. Li J, Wang Y, Yu W, Chen J, Luo J. Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic signifcance. Biochem Biophys Res Commun 2011; 406: 70-73 [PMID: 21295551 DOI: 10.1016/j.bbrc.2011.01.111]
42. Li L, Guo Z, Wang J, Mao Y, Gao Q. Serum miR-18a: a potential marker for hepatitis B virus-related hepatocellular carcinoma screening. Dig Dis Sci 2012; 57: 2910-2916 [PMID: 22865399 DOI: 10.1007/s10620-012-2317-y]
43. Li LM, Hu ZB, Zhou ZX, Chen X, Liu FY, Zhang JF, Shen HB, Zhang CY, Zen K. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res 2010; 70: 9798-9807 [PMID: 21098710 DOI: 10.1158/0008-5472.CAN-10-1001]
44. Li W, Xie L, He X, Li J, Tu K, Wei L, Wu J, Guo Y, Ma X, Zhang P, Pan Z, Hu X, Zhao Y, Xie H, Jiang G, Chen T, Wang J, Zheng S, Cheng J, Wan D, Yang S, Li Y, Gu J. Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int J Cancer 2008; 123: 1616-1622 [PMID: 18649363 DOI: 10.1002/ijc.23693]
45. Liu AM, Yao TJ, Wang W, Wong KF, Lee NP, Fan ST, Poon RT, Gao C, Luk JM. Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open 2012; 2: e000825 [PMID: 22403344 DOI: 10.1136/bmjopen-2012-000825]
46. Liu Y, Xie K, Wen J, Deng M, Li J, Hu Z. A genetic variant in microRNA-122 regulatory region confers risk for chronic hepatitis B virus infection and hepatocellular carcinoma in Han Chinese. J Med Virol 2014; 86: 1669-1674 [PMID: 24995424 DOI: 10.1002/jmv.23996]
47. Meng FL, Wang W, Jia WD. Diagnostic and prognostic significance of serum miR-24-3p in HBV-related hepatocellular carcinoma. Med Oncol 2014; 31: 177 [PMID: 25129312]
48. Qi F, Huang M, Pan Y, Liu Y, Liu J, Wen J, Xie K, Shen H, Ma H, Miao Y, Hu Z. A genetic variant in the promoter region of miR-106b-25 cluster predict clinical outcome of HBV-related hepatocellular carcinoma in Chinese. PLoS One 2014; 9: e85394 [PMID: 24416400 DOI: 10.1371/journal.pone.0085394]
49. Qi P, Cheng SQ, Wang H, Li N, Chen YF, Gao CF. Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS One 2011; 6: e28486 [PMID: 22174818 DOI: 10.1371/journal.pone.0028486]
50. Tan Y, Ge G, Pan T, Wen D, Chen L, Yu X, Zhou X, Gan J. A serum microRNA panel as potential biomarkers for hepatocellular carcinoma related with hepatitis B virus. PLoS One 2014; 9: e107986 [PMID: 25238238 DOI: 10.1371/journal.pone.0107986]
51. Wei X, Tan C, Tang C, Ren G, Xiang T, Qiu Z, Liu R, Wu Z. Epigenetic repression of miR-132 expression by the hepatitis B virus x protein in hepatitis B virus-related hepatocellular carcinoma. Cell Signal 2013; 25: 1037-1043 [PMID: 23376496 DOI: 10.1016/j.cellsig.2013.01.019]
52. Wen Y, Han J, Chen J, Dong J, Xia Y, Liu J, Jiang Y, Dai J, Lu J, Jin G, Wei Q, Shen H, Sun B, Hu Z. Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma. Int J Cancer 2015; 137: 1679-1690 [DOI: 10.1002/ijc.2954425845839]
53. Xiang Y, Fan S, Cao J, Huang S, Zhang LP. Association of the microRNA-499 variants with susceptibility to hepatocellular carcinoma in a Chinese population. Mol Biol Rep 2012; 39: 7019-7023 [PMID: 22311030 DOI: 10.1007/s11033-012-1532-0]
54. Xie Y, Yao Q, Butt AM, Guo J, Tian Z, Bao X, Li H, Meng Q, Lu J. Expression profling of serum microRNA-101 in HBV-associated chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Cancer Biol Ther 2014; 15: 1248-1255 [PMID: 24971953 DOI: 10.4161/cbt.29688]
55. Xing TJ, Jiang DF, Huang JX, Xu ZL. Expression and clinical signifcance of miR-122 and miR-29 in hepatitis B virus-related liver disease. Genet Mol Res 2014; 13: 7912-7918 [PMID: 25299106 DOI: 10.4238/2014.September.29.4]
56. Xu J, Wu C, Che X, Wang L, Yu D, Zhang T, Huang L, Li H, Tan W, Wang C, Lin D. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 2011; 50: 136-142 [PMID: 21229610 DOI: 10.1002/mc.20712]
57. Zhang H, Li QY, Guo ZZ, Guan Y, Du J, Lu YY, Hu YY, Liu P, Huang S, Su SB. Serum levels of microRNAs can specifically predict liver injury of chronic hepatitis B. World J Gastroenterol 2012; 18: 5188-5196 [PMID: 23066312 DOI: 10.3748/wjg.v18. i37.5188]
58. Zhang T, Zhang J, Cui M, Liu F, You X, Du Y, Gao Y, Zhang S, Lu Z, Ye L, Zhang X. Hepatitis B virus X protein inhibits tumor suppressor miR-205 through inducing hypermethylation of miR-205 promoter to enhance carcinogenesis. Neoplasia 2013; 15: 1282-1291 [PMID: 24339740]
59. Zhang ZZ, Liu X, Wang DQ, Teng MK, Niu LW, Huang AL, Liang Z. Hepatitis B virus and hepatocellular carcinoma at the miRNA level. World J Gastroenterol 2011; 17: 3353-3358 [PMID: 21876625 DOI: 10.3748/wjg.v17.i28.3353]
60. Zhao Q, Li T, Qi J, Liu J, Qin C. The miR-545/374a cluster encoded in the Ftx lncRNA is overexpressed in HBV-related hepatocellular carcinoma and promotes tumorigenesis and tumor progression. PLoS One 2014; 9: e109782 [PMID: 25299640 DOI: 10.1371/journal.pone.0109782]
61. Zhou J, Yu L, Gao X, Hu J, Wang J, Dai Z, Wang JF, Zhang Z, Lu S, Huang X, Wang Z, Qiu S, Wang X, Yang G, Sun H, Tang Z, Wu Y, Zhu H, Fan J. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol 2011; 29: 4781-4788 [PMID: 22105822 DOI: 10.1200/JCO.2011.38.2697]
62. Zhu HT, Dong QZ, Sheng YY, Wei JW, Wang G, Zhou HJ, Ren N, Jia HL, Ye QH, Qin LX. MicroRNA-29a-5p is a novel predictor for early recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection. PLoS One 2012; 7: e52393 [PMID: 23285022 DOI: 10.1371/journal.pone.0052393]
63. Li T, Yin J, Yuan L, Wang S, Yang L, Du X, Lu J. Downregulation of microRNA-139 is associated with hepatocellular carcinoma risk and short-term survival. Oncol Rep 2014; 31: 1699-1706 [PMID: 24549282 DOI: 10.3892/or.2014.3032]
64. Liu Y, Zhang Y, Wen J, Liu L, Zhai X, Liu J, Pan S, Chen J, Shen H, Hu Z. A genetic variant in the promoter region of miR-106b-25 cluster and risk of HBV infection and hepatocellular carcinoma. PLoS One 2012; 7: e32230 [PMID: 22393390 DOI: 10.1371/journal. pone.0032230]
65. Chung GE, Yoon JH, Myung SJ, Lee JH, Lee SH, Lee SM, Kim SJ, Hwang SY, Lee HS, Kim CY. High expression of microRNA-15b predicts a low risk of tumor recurrence following curative resection of hepatocellular carcinoma. Oncol Rep 2010; 23: 113-119 [PMID: 19956871]
66. Cong N, Chen H, Bu WZ, Li JP, Liu N, Song JL. miR-146a G& gt; C polymorphisms and risk of hepatocellular carcinoma in a Chinese population. Tumour Biol 2014; 35: 5669-5673 [PMID: 24615520 DOI: 10.1007/s13277-014-1750-2]
67. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 2009; 28: 3526-3536 [PMID: 19617899 DOI: 10.1038/onc.2009.211]
68. Diaz G, Melis M, Tice A, Kleiner DE, Mishra L, Zamboni F, Farci P. Identifcation of microRNAs specifcally expressed in hepatitis C virus-associated hepatocellular carcinoma. Int J Cancer 2013; 133: 816-824 [PMID: 23390000 DOI: 10.1002/ijc.28075]
69. Gramantieri L, Ferracin M, Fornari F, Veronese A, Sabbioni S, Liu CG, Calin GA, Giovannini C, Ferrazzi E, Grazi GL, Croce CM, Bolondi L, Negrini M. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 2007; 67: 6092-6099 [PMID: 17616664 DOI: 10.1158/0008-5472.CAN-06-4607]
70. Hao YX, Wang JP, Zhao LF. Associations between three common MicroRNA polymorphisms and hepatocellular carcinoma risk in Chinese. Asian Pac J Cancer Prev 2014; 14: 6601-6604 [PMID: 24377574]
71. Köberle V, Kronenberger B, Pleli T, Trojan J, Imelmann E, Peveling-Oberhag J, Welker MW, Elhendawy M, Zeuzem S, Piiper A, Waidmann O. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer 2013; 49: 3442-3449 [PMID: 23810247 DOI: 10.1016/j.ejca.2013.06.002]
72. Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, Rebouissou S, Zucman-Rossi J. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 2008; 47: 1955-1963 [PMID: 18433021 DOI: 10.1002/hep.22256]
73. Liu WH, Yeh SH, Lu CC, Yu SL, Chen HY, Lin C Y, Chen DS, Chen PJ. MicroRNA-18a prevents estrogen receptor-alpha expression, promoting proliferation of hepatocellular carcinoma cells. Gastroenterology 2009; 136: 683-693 [PMID: 19027010 DOI: 10.1053/j.gastro.2008.10.029]
74. Lu CY, Lin KY, Tien MT, Wu CT, Uen YH, Tseng TL. Frequent DNA methylation of MiR-129-2 and its potential clinical implication in hepatocellular carcinoma. Genes Chromosomes Cancer 2013; 52: 636-643 [PMID: 23580407 DOI: 10.1002/gcc.22059]
75. Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, Shimotohno K. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2006; 25: 2537-2545 [PMID: 16331254 DOI: 10.1038/sj.onc.1209283]
76. Qu KZ, Zhang K, Li H, Afdhal NH, Albitar M. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol 2011; 45: 355-360 [PMID: 21278583 DOI: 10.1097/MCG.0b013e3181f18ac2]
77. Salvi A, Abeni E, Portolani N, Barlati S, De Petro G. Human hepatocellular carcinoma cell-specific miRNAs reveal the differential expression of miR-24 and miR-27a in cirrhotic/non-cirrhotic HCC. Int J Oncol 2013; 42: 391-402 [PMID: 23229173 DOI: 10.3892/ijo.2012.1716]
78. Sato F, Hatano E, Kitamura K, Myomoto A, Fujiwara T, Takizawa S, Tsuchiya S, Tsujimoto G, Uemoto S, Shimizu K. MicroRNA Profile predicts recurrence after resection in patients with hepatocellular carcinoma within the Milan Criteria. PLoS One 2011; 6: e16435 [PMID: 21298008 DOI: 10.1371/journal.pone.0016435]
79. Shigoka M, Tsuchida A, Matsudo T, Nagakawa Y, Saito H, Suzuki Y, Aoki T, Murakami Y, Toyoda H, Kumada T, Bartenschlager R, Kato N, Ikeda M, Takashina T, Tanaka M, Suzuki R, Oikawa K, Takanashi M, Kuroda M. Deregulation of miR-92a expression is implicated in hepatocellular carcinoma development. Pathol Int 2010; 60: 351-357 [PMID: 20518884 DOI: 10.1111/j.1440-1827.2010.02526. x]
80. Spaniel C, Honda M, Selitsky SR, Yamane D, Shimakami T, Kaneko S, Lanford RE, Lemon SM. microRNA-122 abundance in hepatocellular carcinoma and non-tumor liver tissue from Japanese patients with persistent HCV versus HBV infection. PLoS One 2013; 8: e76867 [PMID: 24130799 DOI: 10.1371/journal. pone.0076867]
81. Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L, Minguez B, Savic R, Ward SC, Thung S, Chiang D Y, Alsinet C, Tovar V, Roayaie S, Schwartz M, Bruix J, Waxman S, Friedman SL, Golub T, Mazzaferro V, Llovet JM. MicroRNA-based Classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology 2011; 140: 1618-1628.e16 [PMID: 21324318 DOI: 10.1053/j.gastro.2011.02.009]
82. Tomimaru Y, Eguchi H, Nagano H, Wada H, Kobayashi S, Marubashi S, Tanemura M, Tomokuni A, Takemasa I, Umeshita K, Kanto T, Doki Y, Mori M. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol 2012; 56: 167-175 [PMID: 21749846 DOI: 10.1016/j.jhep.2011.04.026]
83. Ura S, Honda M, Yamashita T, Ueda T, Takatori H, Nishino R, Sunakozaka H, Sakai Y, Horimoto K, Kaneko S. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology 2009; 49: 1098-1112 [PMID: 19173277 DOI: 10.1002/hep.22749]
84. Zhou B, Dong LP, Jing X Y, Li JS, Yang SJ, Wang JP, Zhao LF. Association between miR-146aG& gt; C and miR-196a2C& gt; T polymorphisms and the risk of hepatocellular carcinoma in a Chinese population. Tumour Biol 2014; 35: 7775-7780 [PMID: 24816919 DOI: 10.1007/s13277-014-2020-z]
85. Liu YX, Long XD, Xi ZF, Ma Y, Huang XY, Yao JG, Wang C, Xing TY, Xia Q. MicroRNA-24 modulates aflatoxin B1-related hepatocellular carcinoma prognosis and tumorigenesis. Biomed Res Int 2014; 2014: 482926 [PMID: 24800232 DOI: 10.1155/2014/482926]
86. Abdalla MA, Haj-Ahmad Y. Promising Candidate Urinary MicroRNA Biomarkers for the Early Detection of Hepatocellular Carcinoma among High-Risk Hepatitis C Virus Egyptian Patients. J Cancer 2012; 3: 19-31 [PMID: 22211142]
87. Bihrer V, Waidmann O, Friedrich-Rust M, Forestier N, Susser S, Haupenthal J, Welker M, Shi Y, Peveling-Oberhag J, Polta A, von Wagner M, Radeke HH, Sarrazin C, Trojan J, Zeuzem S, Kronenberger B, Piiper A. Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma. PLoS One 2011; 6: e26971 [PMID: 22066022 DOI: 10.1371/journal.pone.0026971]
88. El-Garem H, Ammer A, Shehab H, Shaker O, Anwer M, El-Akel W, Omar H. Circulating microRNA, miR-122 and miR-221 signature in Egyptian patients with chronic hepatitis C related hepatocellular carcinoma. World J Hepatol 2014; 6: 818-824 [PMID: 25429320 DOI: 10.4254/wjh.v6.i11.818]
89. Elhelw DS, Mekky RY, El-Ekiaby N, Ahmed R, Eldin MA, El-Sayed M, Abouelkhair MM, Salah A, Zekri AR, Esmat G, Abdelaziz AI. Predictive prognostic role of miR-181a with discrepancy in the liver and serum of genotype 4 hepatitis C virus patients. Biomed Rep 2014; 2: 843-848 [PMID: 25279157 DOI: 10.3892/br.2014.343]
90. Oksuz Z, Serin MS, Kaplan E, Dogen A, Tezcan S, Aslan G, Emekdas G, Sezgin O, Altintas E, Tiftik EN. Serum microRNAs; miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-5p could be used as novel non-invasive biomarkers for HCV-positive cirrhosis and hepatocellular carcinoma. Mol Biol Rep 2015; 42: 713-720 [PMID: 25391771 DOI: 10.1007/s11033-014-3819-9]
91. Varnholt H, Drebber U, Schulze F, Wedemeyer I, Schirmacher P, Dienes HP, Odenthal M. MicroRNA gene expression Profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology 2008; 47: 1223-1232 [PMID: 18307259 DOI: 10.1002/hep.22158]
92. Zhang Y, Wei W, Cheng N, Wang K, Li B, Jiang X, Sun S. Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling. Hepatology 2012; 56: 1631-1640 [PMID: 22610915 DOI: 10.1002/hep.25849]
93. Tan Y, Ge G, Pan T, Wen D, Gan J. A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease. PLoS One 2014; 9: e105192 [PMID: 25141008 DOI: 10.1371/journal.pone.0105192]
94. Li J, Shi W, Gao Y, Yang B, Jing X, Shan S, Wang Y, Du Z. Analysis of microRNA expression profiles in human hepatitis B virus-related hepatocellular carcinoma. Clin Lab 2013; 59: 1009-1015 [PMID: 24273923]
95. Cheung O, Puri P, Eicken C, Contos MJ, Mirshahi F, Maher JW, Kellum JM, Min H, Luketic VA, Sanyal AJ. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology 2008; 48: 1810-1820 [PMID: 19030170 DOI: 10.1002/hep.22569]
96. Estep M, Armistead D, Hossain N, Elarainy H, Goodman Z, Baranova A, Chandhoke V, Younossi ZM. Differential expression of miRNAs in the visceral adipose tissue of patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2010; 32: 487-497 [PMID: 20497147 DOI: 10.1111/j.1365-2036.2010.04366. x]
97. Miyaaki H, Ichikawa T, Kamo Y, Taura N, Honda T, Shibata H, Milazzo M, Fornari F, Gramantieri L, Bolondi L, Nakao K. Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease. Liver Int 2014; 34: e302-e307 [PMID: 24313922 DOI: 10.1111/liv.12429]
98. Pirola CJ, Fernández Gianotti T, Castaño GO, Mallardi P, San Martino J, Mora Gonzalez Lopez Ledesma M, Flichman D, Mirshahi F, Sanyal AJ, Sookoian S. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut 2015; 64: 800-812 [PMID: 24973316 DOI: 10.1136/gutjnl-2014-306996]
99. Padgett KA, Lan RY, Leung PC, Lleo A, Dawson K, Pfeiff J, Mao TK, Coppel RL, Ansari AA, Gershwin ME. Primary biliary cirrhosis is associated with altered hepatic microRNA expression. J Autoimmun 2009; 32: 246-253 [PMID: 19345069 DOI: 10.1016/j.jaut.2009.02.022]
100. Ninomiya M, Kondo Y, Funayama R, Nagashima T, Kogure T, Kakazu E, Kimura O, Ueno Y, Nakayama K, Shimosegawa T. Distinct microRNAs expression Profile in primary biliary cirrhosis and evaluation of miR 505-3p and miR197-3p as novel biomarkers. PLoS One 2013; 8: e66086 [PMID: 23776611 DOI: 10.1371/journal.pone.0066086]
101. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, Mitchell PS, Bennett CF, Pogosova-Agadjanyan EL, Stirewalt DL, Tait JF, Tewari M. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 2011; 108: 5003-5008 [PMID: 21383194 DOI: 10.1073/pnas.1019055108]
102. Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F, Calabrò E, Croce CM, Pastorino U, Sozzi G. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci USA 2011; 108: 3713-3718 [PMID: 21300873 DOI: 10.1073/pnas.1100048108]
103. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J, Zhang CY. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006 [PMID: 18766170 DOI: 10.1038/cr.2008.282]
104. Lynn FC. Meta-regulation: microRNA regulation of glucose and lipid metabolism. Trends Endocrinol Metab 2009; 20: 452-459 [PMID: 19800254 DOI: 10.1016/j.tem.2009.05.007]
105. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, Watts L, Booten SL, Graham M, McKay R, Subramaniam A, Propp S, Lollo BA, Freier S, Bennett CF, Bhanot S, Monia BP. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006; 3: 87-98 [PMID: 16459310 DOI: 10.1016/j.cmet.2006.01.005]
106. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specifc MicroRNA. Science 2005; 309: 1577-1581 [PMID: 16141076 DOI: 10.1126/science.1113329]
107. Chen Y, Shen A, Rider PJ, Yu Y, Wu K, Mu Y, Hao Q, Liu Y, Gong H, Zhu Y, Liu F, Wu J. A liver-specifc microRNA binds to a highly conserved RNA sequence of hepatitis B virus and negatively regulates viral gene expression and replication. FASEB J 2011; 25: 4511-4521 [PMID: 21903935 DOI: 10.1096/fj.11-187781]
108. Wu FL, Jin WB, Li JH, Guo AG. Targets for human encoded microRNAs in HBV genes. Virus Genes 2011; 42: 157-161 [DOI: 10.1007/s11262-010-0555-721113793]
109. Novellino L, Rossi RL, Bonino F, Cavallone D, Abrignani S, Pagani M, Brunetto MR. Circulating hepatitis B surface antigen particles carry hepatocellular microRNAs. PLoS One 2012; 7: e31952 [PMID: 22470417 DOI: 10.1371/journal.pone.0031952]
110. Visani M, de Biase D, Marucci G, Taccioli C, Baruzzi A, Pession A. Definition of miRNAs expression profile in glioblastoma samples: the relevance of non-neoplastic brain reference. PLoS One 2013; 8: e55314 [PMID: 23383149 DOI: 10.1371/journal. pone.0055314]